Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1–Specific VHHs

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity· 2001 · 2,799 citations
2. Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12· 2015 · 227 citations
3. Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma· 2010 · 1,237 citations
4. The Dose-Dependent Tumor Targeting of Antibody–IFNγ Fusion Proteins Reveals an Unexpected Receptor-Trapping Mechanism <i>In Vivo</i>· 2014 · 33 citations
5. Lack of immunoediting in murine pancreatic cancer reversed with neoantigen· 2016 · 181 citations